

Study of activation of the coagulation cascade in patients with chronic spontaneous urticaria

Thesis

Submitted for partial fulfillment of master degree in internal medicine

By

Mustafa Gamil Mahmoud Shams El dine

MB.,Bch., (Ain Shams university)

Under supervision of

Professor Dr/Maged Mohamed Refaat

Professor of Internal Medicine, Allergy and Clinical Immunology.
Faculty of Medicine-Ain Shams University.

Dr/Mohamed Nazmy Farres

Assistant Professor of Internal Medicine, Allergy and Clinical Immunology.
Faculty of Medicine-Ain Shams University.

Dr/ Nermine Abd Elnour Melek

Assistant Professor of Internal Medicine, Allergy and Clinical Immunology.
Faculty of Medicine-Ain Shams University.

2013

Acknowledgment

Thanks to **ALLAH** who have lightened my path to become a humble student of a noble profession and granted me the ability to accomplish this work.

I would like to express my deepest gratitude and appreciation for **Professor Dr/Maged Mohamed Refaat**, one of the most prominent Professors of internal medicine, Faculty of Medicine, Ain Shams University, for his kind supervision and encouragement as well as his moral support throughout the whole work till it accomplished. It was a great honor to work under his supervision.

I am also deeply thankful to, **Dr/Mohamed Nazmy Farres**, Assistant Professor of Internal Medicine, Allergy and Clinical Immunology. Faculty of Medicine-Ain Shams University.who shared in the conductance of this work with his valuable support, guidance and precious instructions.

I would like to express gratitude and deep thanks to **Dr/Nermine AbdElnour Melek** Assistant Professor of Internal Medicine, Allergy and Clinical Immunology. Faculty of Medicine-Ain Shams University.for her great help and supervision of this work.

I would like to express my heartfelt gratitude to my patients for their help and cooperation.

Contents

	Pages
Acknowledgment	
List of contents	
List of Tables	
List of Figures	
List of Abbreviations	
Introduction	1-2
Aim of the study	3
Review of Literature:	
Chapter 1 : Chronic urticaria	4-40
Chapter 2 : Hemostasis	41-64
Subjects and methods	65-69
Results	70-84
Discussion	85-95
Summery	96-99
Conclusion	100
Recommendations	101
References	102-133
Arabic Summary	134-137

List of Tables

Table Number	Table Name	Page
Table(1)	Characteristics of cases and controls.	70
Table(2)	Comparison between cases with active CSU and controls as regards baseline levels of D-dimer and factor VII.	71
Table(3)	Comparison of baseline levels of D-dimer and factor VII among active CSU cases according to the different grades of severity.	74
Table(4)	Comparison of baseline levels of D-dimer and factor VII between males and females among both study groups.	77
Table(5)	Correlations of age and body mass index with baseline levels of D-dimer among cases and controls.	78
Table(6)	Correlations of age and body mass index with baseline levels of factor VII among cases and controls.	78
Table(7)	Comparison between D-dimer and factor VII levels at baseline among active CSU cases with their corresponding levels after remission.	80
Table(8)	Comparison of D-dimer and factor VII levels between cases after remission and levels among controls.	82

List of figures

Figure Number	Figure Name	Page
FIGURE I	Normal hemostasis	43
FIGURE II	Anti- and procoagulant activities of endothelium.	45
FIGURE III	Platelet adhesion and aggregation	48
FIGURE IV	The coagulation cascade.	53
FIGURE V	Illustration of the conversion of factor X to factor Xa via the extrinsic pathway	58
FIGURE VI	Role of thrombin in hemostasis and cellular activation.	61
FIGURE VII	Fibrinolytic system	64
Figure (1)	Comparison between cases with active CSU and controls as regards baseline levels of D-dimer.	72
Figure (2)	Comparison between cases with active CSU and controls as regards baseline levels of factor VII.	73
Figure (3)	Correlation between D-dimer levels among cases at baseline and grades of disease severity.	75
Figure (4)	Correlation between factor VII levels among cases at baseline and grades of disease severity.	76
Figure (5)	Correlation between D-dimer levels and factor VII levels at baseline among cases.	79
Figure (6)	Correlation between D-dimer levels and factor VII levels among controls.	80
Figure (7)	Levels of D-dimer and factor VII among active CSU cases at baseline and their corresponding levels after remission.	81
Figure (8)	Comparison between D-dimer levels among cases after remission and D-dimer levels among controls.	83
Figure (9)	Comparison between factor VII levels among cases after remission and factor VII levels among controls.	84

List of Abbreviations

ACE	angiotensin-converting enzyme
ADP	adenosine diphosphate
APST	autologous plasma skin test
APTT	activated partial thromboplastin time
ASST	autologous serum skin test
AST	Autologous serum therapy
BMI	Body Mass Index
CAU	chronic autoimmune urticaria
CIU	chronic idiopathic urticaria
COAT	Collagen And Thrombin
COX-2	cyclo-oxygenase-2
CSU	Chronic spontaneous urticari
CRP	C REACTIVCE ROTIEN
CU	Chronic urticaria
DIC	disseminated intravascular coagulation
ECM	extracellular matrix
ELISA	Enzyme linked immunosorbent assay
ESR	Erythrocyte sedimentation rate
FcεRI	functionally active autoantibodies to the high affinity IgE receptor
FSPs	fibrin split products
FVIIa	activated factor VII
GpIb	glycoprotein Ib
IL-1	interleukin-1
INR	the international normalized ratio
IQR	interquartile range
IU	International units
IVIg	intravenous immunoglobulin
NSAIDs	nonsteroidal anti-inflammatory drugs
PAIs	inhibitors of plasminogen activator
PARs	protease activated receptors
PAs	plasminogen activators

PDGF	platelet-derived growth factor
PGI2	prostacyclin
PT	Prothrombin Time
PTT	partial thromboplastin time
PUVA	Phototherapy with ultraviolet light
QoL	quality of life
SD	standard deviation
TF	tissue factor
TFPI	tissue factor pathway inhibitor
TGF-β	Tumor Growth Factor Beta
TNF	tumor necrosis factor
TNF α	Tumor Necrosis Factor Alpha
t-PA	tissue- type plasminogen activator
TxA2	thromboxane A2
<i>u-PA</i>	<i>Urokinase-like PA</i>
UV	Urticarial vasculitis
vWF	von Willebrand factor

Introduction

Chronic urticaria (CU) is a relatively common disorder with an estimated 0.5% lifetime prevalence in the general population. The condition can be severe and debilitating and may impair quality of life (*Sagi et al., 2011*). This disease is characterized by at least 6 weeks of almost daily episodes of intensely pruritic cutaneous wheals that typically last less than 24 hours and are not associated with residual pigmentation (*Saavedra and Sur, 2011*).

In spontaneous urticaria, the most common type, the hives seem to arise without provocation (*Maurer and Grabbe, 2008*).

Studies carried out on chronic spontaneous urticaria during the last two decades have depicted an autoimmune pathogenesis mediated by functionally active autoantibodies to the high affinity IgE receptor (FcεRI) or to IgE, which are able to induce histamine release from basophils and mast cells. However, such a mechanism can explain the disease in less than 50% of patients (*Ghosh, 2009*).

Asero et al., 2007 have shown that an additional pathogenic mechanism in patients with chronic urticaria is the activation of the coagulation cascade. They described enhanced thrombin generation in patients with CU. They argued that thrombin generation is accelerated by the increase of tissue factor expressed in dermal tissues via the activation of extrinsic coagulation. They advocated that the accelerated generation of thrombin would then activate mast cells and increase endothelial permeability (*Asero et al., 2006*).

However, Kaplan and Greaves 2009 recently challenged this scenario on several points: (i) lack of evidence for thrombin-dependent activation of human mast cells, (ii) immediate inactivation of thrombin by plasma inhibitors, (iii) possible presence of yet to be defined plasma factor other than thrombin that leads to an increase in endothelial permeability.

Aim of the study:

The present study aims to assess the possibility of activation of the coagulation cascade in patients with chronic spontaneous urticaria, and to correlate this activation with the severity of chronic urticaria.

Chronic urticaria

Introduction

Urticaria (from the Latin word *urtica*, (to burn) orhives), are a kind of skin rash notable for dark red, raised, itchy bumps (*OED, 2000*).

It affects 15-20% of the population once or more during a lifetime (*Caliskaner et al., 2004*).

In around 30% patients of urticaria, attacks often recur for months or years. Chronic urticaria (CU) is defined by recurrent episodes occurring at least twice a week for 6 weeks (*Clive et al., 2002*).

Females are more commonly affected than males (*Deacock, 2008*).

Establishing the cause of CU is difficult and at times almost impossible. This renders cause specific management difficult and frustration on part of the patient and the treating physician. Also, CU is associated with lower quality of life (QoL) levels (*Ugu et al., 2008*).

Recent advances in our understanding of its pathogenesis include the finding of autoantibodies to mast cell receptors in nearly half of patients. This possibility of an autoimmune basis to chronic idiopathic urticaria (CIU) is now widely explored (*Sharma et al., 2004*).

Urticaria represents a transient edema within the dermis; the individual urticarial lesions characteristically clear within hours. It is a vascular reaction of the skin, triggered by many known as well as unknown factors that result in liberation of vasoactive substances such as histamine, prostaglandins, and kinins (**Buss et al., 2007**). Most lesions of urticaria are small, less than 10 mm, but individual large lesions of 6–10 cm may occur — the so-called giant urticaria. Clinically, urticaria is classified into the acute (duration < six weeks) and chronic (duration > six weeks) types (**Grattan et al., 2002**).

‘Episodic’ urticaria, which occurs intermittently but recurrently over months or years, is also recognized (**Deacock, 2008**).

CU accounts for 25% of urticaria (**Greaves, 1995**). And the prevalence of CU is 0.1%-0.6% (**Gaig et al., 2004**). Almost 40% of CU patients continue to experience urticarial wheals 10 years later (**Baiardini et al., 2003**).

CU has detrimental effects on the quality of life (QOL) and is associated with poorer general health and reduced emotional well-being (**Baiardini et al., 2003**).

As a result, CU has a large impact on society in terms of healthcare costs (**DeLong et al., 2008**). Patients with refractory CU do not respond to standard treatments with antihistamines or

additional immunomodulators that are, in a few cases, unsafe when used for prolonged times.

CU is a heterogeneous disorder and includes idiopathic, autoimmune, and physical urticaria and vasculitis (***Grattan et al., 2002***). For more than 50% of patients with CU, the underlying cause has not been identified (***Greaves, 2003***).

However, up to one-third of patients with chronic idiopathic urticaria have autoantibodies to FcεRI (a high-affinity receptor for IgE), and about 10% have IgE autoantibodies. These autoantibodies can cause mast cell degranulation, and most CU symptoms result from the degranulation of skin mast cells (***Sabroe et al., 2002***).

Histopathology:

The histological appearance of the skin in CIU resembles that of a late phase reaction. Although the infiltrate in patients with CAU is characterized by more prominent granulocyte infiltrate than that of non-autoimmune patients, the frequency of other infiltrating cells is similar in both groups, although there is a slight increase in serum tryptase and cytokines in CAU patients. These small differences are too insignificant to be used as a diagnostic tool (*Grattan et al., 1990*).

Pathophysiology:

The mast cell is believed to be the major effector cell in most forms of urticaria, though other cell types may be involved. Degranulation of mast cells with release of histamine is central to the development of wheals and angioedema. Urticaria is due to a local increase in permeability of capillaries and venules. These changes are dependent on activation of the cutaneous mast cells, which contain a range of mediators predominantly histamine. The mast cells respond with a lowered threshold of releasability (*Khalaf et al., 2008*).

Vascular permeability in skin is produced by the interaction of both H₁ and H₂ histamine receptors. Activation of H₁ receptors in the skin induces itching, flare, erythema, whealing and contraction of smooth muscle in respiratory and gastrointestinal tract. Activation of H₂ receptors contributes to erythema and whealing in the skin. Chronic autoimmune urticaria is caused by anti-Fc ϵ RI and less frequently, by anti-IgE autoantibodies that lead to mast cell and basophil activation. A few preclinical investigations have demonstrated an upregulation of TNF- α in patients with CIU. This is in contrast to acute urticaria where TNF- α does not appear to play as important of a role in the inflammatory response. This may explain why patients with CIU do not typically respond to usual therapies for acute urticaria. It